Company: GSHRW
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001213900-25-109193
Chunk: 15

Company: Gesher Acquisition Corp. II
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
ains and losses resulting from the change in fair value of these securities are included in income
from investments held in the Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair values
of investments held in the Trust Account are determined using available market information. As of September 30, 2025, all of the assets
held in the Trust Account, $147,300,306, were held in a money market fund and none of the assets were held in cash.

Concentration
of Credit Risk

Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution,
which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. Any loss incurred or a lack of access
to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

Offering
Costs

The
Company complies with the requirements of FASB ASC Topic 340-10-S99, “Other Assets and Deferred Costs”, and SEC Staff
Accounting Bulletin Topic 5A, “Expenses of Offering.” Offering costs consist principally of professional and registration
fees that are related to the Initial Public Offering. FASB ASC Topic 470-20, “Debt with Conversion and Other Options,”
addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applied this
guidance to allocate Initial Public Offering proceeds from the Public Units between Public Shares and Public Warrants, using the residual
method by allocating Initial Public Offering proceeds first to assigned value of the Public Warrants and then to the Public Shares. Offering
costs allocated to the Public Warrants and Private Placement Units were shared to shareholders’ equity (deficit). Warrants, after Management’s
evaluation, were accounted for under equity treatment.

Transaction
costs amounted to $8,409,601, consisting of $2,875,000 of cash underwriting fee, the Deferred Underwriting Fee of $5,031,250, and $503,351
of other offering costs.

Fair
Value of Financial Instruments

The
fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC Topic 820, “Fair
Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying condensed balance sheets,
primarily due to its short-term nature.

Income
Taxes

The